Orion Oyj (OTCMKTS:ORINY) Reaches New 1-Year High at $25.15

Orion Oyj (OTCMKTS:ORINY) reached a new 52-week high during mid-day trading on Monday . The company traded as high as $25.15 and last traded at $25.15, with a volume of 481 shares. The stock had previously closed at $21.70.

Orion Oyj Trading Up 15.9 %

The stock’s fifty day simple moving average is $21.74 and its 200-day simple moving average is $20.39. The firm has a market cap of $7.10 billion, a PE ratio of 25.83 and a beta of 0.19. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.78 and a quick ratio of 1.00.

Orion Oyj Company Profile

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson’s disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer.